Immunotherapy trial results transforming care for rare skin cancer
April 19, 2016
| By Susan Keown / Fred Hutch News Service
With few remaining options for treating his aggressive Merkel cell carcinoma, Stan Collender joined a clinical trial of the immune-modulating drug pembrolizumab. The trial's results are giving new hope to people with this rare cancer.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.